Rani Therapeutics (RANI) said late Wednesday that new data from a preclinical study evaluating the oral delivery of semaglutide via the RaniPill, or RT-116, capsule demonstrated comparable "bioavailability, pharmacokinetics, and weight loss to subcutaneous administration."
The company said the new data adds to the "growing body of evidence" about RaniPill's potential to enable oral delivery of multiple obesity treatments. Shares jumped more than 42% in premarket activity Thursday.
The company plans to undertake a phase 1 clinical trial of RT-114 containing a GLP-1/GLP-2 dual agonist. The obesity trial will begin this year in partnership with ProGen.
Rani said semaglutide is currently only available as a subcutaneous injection to treat obesity. Novo Nordisk markets the treatment under the brand name Wegovy in the US.
Price: 2.05, Change: +0.61, Percent Change: +42.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.